Daiichi Sankyo’s AML Drug Among Nine CHMP Hopefuls
EMA Panel Poised To Adopt Opinion On EU-Wide Approval Of New Drugs
Will regulators in the EU follow their US counterparts in requiring more efficacy data for Daiichi Sankyo’s acute myeloid leukemia drug quizartinib, which is already approved in Japan?
